MyMD Pharmaceuticals Inc (MYMD) Stock
MYMD is no longer traded. MyMD Pharmaceuticals was delisted from the Nasdaq in September 2024.
Prices on this page are historical; the last trade was September 24, 2024 at $1.33.
MyMD Pharmaceuticals stock price history
MYMD final trading statistics
- Final close
- $1.33
- Final trading day
- Sep 24, 2024
- Market cap at delisting
- $3.15M
- Shares outstanding
- 2.37M
- Final 52-week range
- $0.11 – $3.84
- Avg. volume (final 3 mo.)
- 40,163
- All-time high (split-adj.)
- $808704.00 · Sep 2009
- All-time low (split-adj.)
- $1.19 · Sep 2024
- Return since IPO
- -100.0%
- Beta
- 2.69
- Book value / share
- $4.54
- Price / book
- 0.29
MyMD Pharmaceuticals annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $0.00 | -$4.0M | -$3.03 |
| FY2022 | $0.00 | -$15.1M | -$94.49 |
| FY2021 | $0.00 | -$29.9M | -$362.03 |
| FY2020 | $0.00 | -$10.7M | -$147.29 |
| FY2019 | $1.58M | -$3.9M | -$7.90 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About MyMD Pharmaceuticals Inc
MyMD Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
MyMD Pharmaceuticals stock FAQ
What happened to MyMD Pharmaceuticals stock?
MyMD Pharmaceuticals stock was delisted from the Nasdaq. Its final close was $1.33 on September 24, 2024.
Is MYMD stock still trading?
No. MYMD was delisted from the Nasdaq in September 2024 and no longer trades on a U.S. exchange.
What was the last price of MYMD stock?
MYMD closed at $1.33 on its final trading day, September 24, 2024, for a market value of about $3.15M.
What were MyMD Pharmaceuticals's revenue and earnings in its last full fiscal year?
MyMD Pharmaceuticals reported revenue of $0.00 and net income of -$4.0M in fiscal 2023, its last full year as a public company.
When did MyMD Pharmaceuticals go public?
MyMD Pharmaceuticals Inc stock began trading on January 23, 2014.